MA47359A - Récepteurs de lymphocytes t à appariement amélioré - Google Patents
Récepteurs de lymphocytes t à appariement amélioréInfo
- Publication number
- MA47359A MA47359A MA047359A MA47359A MA47359A MA 47359 A MA47359 A MA 47359A MA 047359 A MA047359 A MA 047359A MA 47359 A MA47359 A MA 47359A MA 47359 A MA47359 A MA 47359A
- Authority
- MA
- Morocco
- Prior art keywords
- lymphocyte receptors
- pairing
- enhanced
- enhanced pairing
- lymphocyte
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662497895P | 2016-12-08 | 2016-12-08 | |
| DE102016123893.7A DE102016123893A1 (de) | 2016-12-08 | 2016-12-08 | T-Zellrezeptoren mit verbesserter Bindung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47359A true MA47359A (fr) | 2019-12-04 |
Family
ID=62201182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047359A MA47359A (fr) | 2016-12-08 | 2017-12-06 | Récepteurs de lymphocytes t à appariement amélioré |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11072645B2 (fr) |
| EP (1) | EP3551653B1 (fr) |
| JP (1) | JP7346294B2 (fr) |
| CN (1) | CN110099923A (fr) |
| AU (1) | AU2017371260C1 (fr) |
| BR (1) | BR112019010803A2 (fr) |
| CA (1) | CA3045230A1 (fr) |
| CR (1) | CR20190280A (fr) |
| DE (1) | DE102016123893A1 (fr) |
| MA (1) | MA47359A (fr) |
| MX (1) | MX2019006726A (fr) |
| PE (1) | PE20191150A1 (fr) |
| TW (1) | TWI710572B (fr) |
| WO (1) | WO2018104407A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| MD3551221T2 (ro) | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| DE102017125888A1 (de) | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| WO2019086665A1 (fr) | 2017-11-06 | 2019-05-09 | Immatics Biotechnologies Gmbh | Nouveaux récepteurs de lymphocytes t modifiés et immunothérapie les utilisant |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20230132241A1 (en) | 2020-01-15 | 2023-04-27 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (fr) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Procédés d'isolement de lymphocytes t sélectionnés cd8+ |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| WO2022184805A1 (fr) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité |
| WO2022233956A1 (fr) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Protéines de liaison à l'antigène se liant de manière spécifique à prame |
| JP2024529467A (ja) | 2021-07-27 | 2024-08-06 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｃｔ４５に特異的に結合する抗原結合タンパク質 |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081925A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Traitement combiné de thérapie cellulaire adoptive et compositions associées |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4198052A1 (fr) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides et protéines de liaison d'antigène pour utilisation dans l'immunothérapie contre le carcinome hépatocellulaire fibrolamellaire (fl-hcc) et autres cancers |
| WO2023212655A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| EP4519418A1 (fr) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Procédés d'amélioration de l'efficacité d'un lymphocyte t |
| EP4750807A1 (fr) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Nouveaux récepteurs de lymphocytes t ciblant un antigène associé au mélanome (mage) b2 et thérapie immunitaire l'utilisant |
| EP4750806A1 (fr) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Protéines de liaison à l'antigène dirigées contre mageb2 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026008886A1 (fr) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Moyens et procédés de quantification de l'expression d'une cible |
| WO2026025031A1 (fr) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Arnm codant pour une molécule de tcer mageb2 |
| WO2026033136A1 (fr) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Modalités de traitement avancées pour des cellules immunitaires modifiées par tcr anti-prame |
| WO2026096575A1 (fr) | 2024-10-29 | 2026-05-07 | Modernatx, Inc. | Arnm codant pour des polypeptides d'épitope de prame concatémériques |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2244744A1 (fr) * | 1996-02-01 | 1997-08-07 | University Of Florida | Compositions de genes lyst1 et lyst2 et leurs procedes d'utilisation |
| CA2366059A1 (fr) | 1999-03-02 | 2000-09-08 | Ludwig Institute For Cancer Research | Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer |
| CA2393730A1 (fr) | 1999-12-13 | 2001-06-14 | Epimmune Inc. | Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i |
| AU2002227498A1 (en) | 2000-07-31 | 2002-02-13 | Kyogo Itoh | Tumor antigen |
| CA2481304A1 (fr) | 2002-03-27 | 2003-10-09 | Patrick Hwu | Methode de traitement du cancer chez les humains |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| DE10313819A1 (de) | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| JP2007519910A (ja) | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 腫瘍関連ペプチドの同定および定量方法 |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| CA2598889A1 (fr) | 2005-02-24 | 2006-08-31 | Cemines, Inc. | Compositions et procedes de classification d'echantillons biologiques |
| EP1717245B1 (fr) | 2005-04-26 | 2011-06-08 | Immatics Biotechnologies GmbH | Epitopes de lymphocytes T provenant du récepteur immature de laminine (antigène oncofoetal) et leurs applications médicales |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| SI1760089T1 (sl) | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| HUE025636T2 (en) | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| RS54204B1 (sr) | 2007-07-27 | 2015-12-31 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv tumora mozga |
| NZ582823A (en) | 2007-07-27 | 2012-04-27 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| EP2288700B1 (fr) * | 2008-05-09 | 2017-02-08 | Agency for Science, Technology And Research | Récepteur des cellules t (tcr) exogène réactif à un épitope du hbv et ses utilisations |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| WO2010037395A2 (fr) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
| GB0917094D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US20130011496A1 (en) | 2009-11-25 | 2013-01-10 | Ludwig Institute For Cancer Research Ltd. | Cancer testis antigens as biomarkers in non-small cell lung cancer |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US9114100B2 (en) | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CN101870725B (zh) | 2010-06-29 | 2012-06-27 | 郑州大学 | Mage-4抗肿瘤ctl表位肽及其应用 |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| SG191154A1 (en) | 2010-12-14 | 2013-07-31 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| AU2012302778B2 (en) | 2011-08-31 | 2016-11-24 | Mie University | Vaccine preparation for cancer treatment |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| AU2014235968B2 (en) | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| PE20150600A1 (es) | 2013-10-15 | 2015-06-03 | Vignolo Carlos Alberto Ibanez | CICLO - BICICLETA HIBRIDA MOTORIZADA 2 x 2 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| WO2015172843A1 (fr) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Méthodes et kits destinés au diagnostic du cancer |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| GB2528124A (en) | 2014-07-11 | 2016-01-13 | Nec Corp | Communication system |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| TWI617841B (zh) | 2014-10-22 | 2018-03-11 | 英特爾股份有限公司 | 用於光學系統的防雲紋圖樣擴散器 |
| WO2016064317A1 (fr) | 2014-10-24 | 2016-04-28 | Telefonaktiebolaget L M Ericsson (Publ) | Procédé et système de transmission de csi-rs |
| CN104460328B (zh) | 2014-10-29 | 2019-05-10 | 小米科技有限责任公司 | 基于设定场景模式的智能设备控制方法和装置 |
| US9771536B2 (en) | 2014-10-30 | 2017-09-26 | EcoGensus LLC | Solid fuel composition formed from mixed solid waste |
| DE102014016105A1 (de) | 2014-10-30 | 2016-05-04 | Head Technology Gmbh | Superelastische Schlägersaite |
| US20190030071A1 (en) | 2014-11-03 | 2019-01-31 | IMMURES S.r.I. | T cell receptors |
| MA40904A (fr) | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
| EP3215069B1 (fr) | 2014-11-04 | 2023-03-08 | Spinal Stabilization Technologies LLC | Prothèse nucléaire implantable percutanée |
| CA2967241C (fr) | 2014-11-17 | 2023-01-31 | Mitrassist Medical Ltd. | Prothese de valvule cardiaque |
| KR20170054544A (ko) | 2014-11-20 | 2017-05-17 | 에이비비 슈바이쯔 아게 | 전자기 브레이크 시스템 및 금속 제조 프로세스에서 용융 금속 유동을 제어하는 방법 |
| DE102014223758A1 (de) | 2014-11-20 | 2016-05-25 | Windmöller & Hölscher Kg | Kontaktwalze |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| EP3067366A1 (fr) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Thérapie génique liée au récepteur de lymphocytes T combinés du cancer contre des épitopes restreints au CMH classe I ou classe I de l'antigène tumoral NY-ESO-1 |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017060201A1 (fr) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
| CN105219714A (zh) | 2015-10-20 | 2016-01-06 | 上海隆耀生物科技有限公司 | 一种用于激活肺癌特异性免疫反应的试剂盒 |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| JP7722629B2 (ja) | 2017-07-04 | 2025-08-13 | キュアバック エスイー | 新規核酸分子 |
| MX2020001879A (es) | 2017-08-18 | 2020-07-29 | Gritstone Oncology Inc | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. |
| CN111315769A (zh) | 2017-09-06 | 2020-06-19 | 加州理工学院 | 信号传导和抗原呈递双功能受体(sabr) |
| US11866731B2 (en) | 2017-11-10 | 2024-01-09 | Chineo Medical Technology Co., Ltd | Modified immune cells and uses thereof |
| AU2018395397A1 (en) | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| ES2935702T3 (es) | 2018-04-11 | 2023-03-09 | Enterome S A | Péptidos antigénicos para la prevención y el tratamiento del cáncer |
| CN112512538A (zh) | 2018-05-18 | 2021-03-16 | 国家儿童医疗中心 | 改进的靶向t细胞疗法 |
| TW202000907A (zh) | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
| CA3102254A1 (fr) | 2018-06-04 | 2019-12-12 | Apo-T B.V. | Procedes et moyens pour attirer des cellules immunitaires effectrices vers des cellules tumorales |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| MA55911A (fr) | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Lymphocytes t génétiquement modifiés |
| MX2021015946A (es) | 2019-06-18 | 2022-04-18 | Regeneron Pharma | Receptores de linfocitos t de mage-a4 y métodos de uso de estos. |
-
2016
- 2016-12-08 DE DE102016123893.7A patent/DE102016123893A1/de not_active Withdrawn
-
2017
- 2017-12-06 EP EP17825761.4A patent/EP3551653B1/fr active Active
- 2017-12-06 MX MX2019006726A patent/MX2019006726A/es unknown
- 2017-12-06 WO PCT/EP2017/081745 patent/WO2018104407A1/fr not_active Ceased
- 2017-12-06 PE PE2019001163A patent/PE20191150A1/es unknown
- 2017-12-06 CR CR20190280A patent/CR20190280A/es unknown
- 2017-12-06 BR BR112019010803-3A patent/BR112019010803A2/pt not_active Application Discontinuation
- 2017-12-06 US US15/833,778 patent/US11072645B2/en active Active
- 2017-12-06 JP JP2019529260A patent/JP7346294B2/ja active Active
- 2017-12-06 AU AU2017371260A patent/AU2017371260C1/en not_active Ceased
- 2017-12-06 CN CN201780075297.XA patent/CN110099923A/zh active Pending
- 2017-12-06 MA MA047359A patent/MA47359A/fr unknown
- 2017-12-06 CA CA3045230A patent/CA3045230A1/fr active Pending
- 2017-12-08 TW TW106143062A patent/TWI710572B/zh not_active IP Right Cessation
-
2021
- 2021-06-22 US US17/354,555 patent/US12297252B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201827460A (zh) | 2018-08-01 |
| AU2017371260B2 (en) | 2020-07-23 |
| CA3045230A1 (fr) | 2018-06-14 |
| AU2017371260C1 (en) | 2020-11-19 |
| WO2018104407A1 (fr) | 2018-06-14 |
| US12297252B2 (en) | 2025-05-13 |
| MX2019006726A (es) | 2019-09-04 |
| EP3551653B1 (fr) | 2023-11-01 |
| AU2017371260A1 (en) | 2019-06-20 |
| US20210380659A1 (en) | 2021-12-09 |
| TWI710572B (zh) | 2020-11-21 |
| BR112019010803A2 (pt) | 2019-10-01 |
| PE20191150A1 (es) | 2019-09-02 |
| US20180162922A1 (en) | 2018-06-14 |
| JP7346294B2 (ja) | 2023-09-19 |
| US11072645B2 (en) | 2021-07-27 |
| JP2020500525A (ja) | 2020-01-16 |
| EP3551653A1 (fr) | 2019-10-16 |
| CN110099923A (zh) | 2019-08-06 |
| CR20190280A (es) | 2019-10-07 |
| DE102016123893A1 (de) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3494133T (pt) | Recetores de células t anti-kras-g12d | |
| MA50651A (fr) | Récepteurs de lymphocytes t reconnaissant p53 mutée | |
| DK3440106T3 (da) | T-cellereceptorer | |
| DK3440105T3 (da) | T-cellereceptorer | |
| EP3813864A4 (fr) | Antagonistes antitumoraux | |
| IL260151A (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex | |
| PT3223850T (pt) | Receptores de células t anti-kras mutado | |
| EP3528851A4 (fr) | Récepteurs antigéniques chimériques hétérodimérisables à base de céréblon | |
| EP3383893A4 (fr) | Récepteur de lymphocytes t à domaine variable unique | |
| EP3344295A4 (fr) | Récepteurs d'antigène chimère tn anti-sialyle | |
| EP3521427A4 (fr) | Co-récepteur de récepteur odorant | |
| EP3424053A4 (fr) | Fil à base de liquide | |
| EP3356856A4 (fr) | Vérification d'ambiguïté basée sur un moniteur et destinée à une qualité de navigation améliorée | |
| EP3321955A4 (fr) | Dispositif de séparation de plaquette | |
| FR3042250B1 (fr) | Joint a section constante | |
| EP3475167A4 (fr) | Système de siège à agencement décalé | |
| EP3515503A4 (fr) | Lymphocytes modifiés | |
| DE112016000423T8 (de) | Abschnittslinienerkennungsvorrichtung | |
| EP3369669A4 (fr) | Récipient à délamination | |
| EP3533312A4 (fr) | Machine autotractée à pousser | |
| EP3468396A4 (fr) | Capsules de mélasse à chicha | |
| EP3529267C0 (fr) | Récepteur de lymphocytes t | |
| EP3366962A4 (fr) | Clapet à cône | |
| EP3638783A4 (fr) | Interruption ciblée de récepteurs de lymphocytes t et/ou de hla | |
| DK3449990T3 (da) | Separationsindretning |